An investigational malaria vaccine — regarded as promising after earlier clinical trials — continued to show efficacy in African children in initial results from a large phase III trial, researchers reported.
Children who got the vaccine as intended had about a 44% reduction in the risk of a first clinical episode of the disease, compared with those who got a non-malaria comparator vaccine, according to Mary Hamel, MD, of the CDC, and colleagues.
The vaccine, dubbed RTS,S/AS01, also protected against severe disease, Hamel and colleagues reported online in the New England Journal of Medicine.
An investigational malaria vaccine — regarded as promising after earlier clinical trials — continued to show efficacy in African children in initial results from a large phase III trial, researchers reported.
Children who got the vaccine as intended had about a 44% reduction in the risk of a first clinical episode of the disease, compared with those who got a non-malaria comparator vaccine, according to Mary Hamel, MD, of the CDC, and colleagues.
The vaccine, dubbed RTS,S/AS01, also protected against severe disease, Hamel and colleagues reported online in the New England Journal of Medicine.